Rhone Ma Holdings (5278) Fair Value & Analysis
Healthcare · MY · Market cap 146M MYR
Fair value as of: Jun 25, 2026
From 26 valuation models · updated 4 days ago
Share price −4.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.5694 MYR – 0.6939 MYR · fair‑value band 1.05 MYR – 1.76 MYR · the 0.6450 MYR price screens below the 1.40 MYR fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Rhone Ma Holdings (5278) currently trades at 0.6450 MYR, while our model-based Fair Value estimate is 1.40 MYR — implying the stock looks roughly 117.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Rhone Ma Holdings generated revenue of 227M MYR at a net margin of 6.3%. Revenue grew 7.6% year over year. It earns a return on equity of 7.9%. Net debt stands at 7.3M MYR. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of biotechnology and animal health products primarily in Malaysia. The company operates through Animal Health Products and Food Equipment; Food Ingredients; and others segments. It offers diagnostic laboratory analysis and consultation services to veterinary, agriculture, and food industries; tests and diagnostics services for human healthcare; and veterinary advisory services, as well as trades in animal health products. The company also undertakes research and development activities related to animal health, food safety, and agriculture; distributes human healthcare and related products; wholesales and distributes pharmaceutical and veterinary products, including animal feeds; and distributes and supplies food ingredients to manufacturers of food and beverage industries. In addition, the company involved in the raising, breeding, and production of semi-domestic…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Rhone Ma Holdings reported revenue of 224M MYR in FY2025 versus 169M MYR in FY2021, a compound +7.2%/yr. Reported net income was 14.2M MYR in FY2025, compounding +5.9%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Rhone Ma Holdings (5278) undervalued?
What is the fair value of 5278?
What is the quality score of 5278?
What is the revenue of Rhone Ma Holdings (5278)?
What is the net profit margin of 5278?
Does Rhone Ma Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.